Anti-LGI1 encephalitis …

Neuro-Oncology

Updated 10.03.2024
Released 05.08.2018
Expires For CME 10.03.2027

Anti-LGI1 encephalitis

Authors: Sarosh R Irani MD, Sudarshini Ramanathan MD

See Contributor Disclosures

Editor: Francesc Graus MD PhD

Anti-LGI1 encephalitis

In This Article

Quick Link

Introduction

Overview

In 2010, antibodies to leucine-rich glioma inactivated 1 (LGI1) were first described as a distinct serological entity. In this review, we evaluate the historical and diagnostic evolution of this condition as well as the potential immunological and genetic contributors to disease pathogenesis. Firstly, we discuss the common epilepsy presentations in these patients, with particular attention to the faciobrachial dystonic seizures, a pathognomonic association of this condition, as well as other associated seizure semiologies. Although cognitive impairment may be a presenting feature or, more commonly, follow the development of faciobrachial dystonic seizures, it also remains the most significant residual disability that can impair patients’ ability to return to functional independence. Therefore, secondly, we also explore the cognitive profiles of these patients and measures of their quality of life. Thirdly, although there are characteristic peripheral, CSF, and MRI findings in a subgroup of patients with LGI1-antibody autoimmune encephalitis, in many patients these investigations can be normal and, hence, noncontributory to diagnosis. Finally, the majority of patients are responsive to immunotherapy. Early recognition and institution of immunotherapy and achieving seizure control is crucial to optimize long-term outcomes and should be a major future therapeutic goal.

Key points

	• LGI1-antibody seropositivity is most commonly associated with limbic encephalitis, with a high incidence of seizures and cognitive impairment.
	• Faciobrachial dystonic seizures are exclusively associated with LGI1 antibodies and may predate the onset of cognitive impairment.
	• Although typical findings on investigation include hyponatremia and medial temporal lobe hyperintensity or swelling on MRI, more than half the patients with LGI1 antibodies may have unremarkable findings.
	• Laboratories should stop testing VGKC-antibodies as VGKC-antibody positivity, in the absence of antibodies to LGI1 and CASPR2, is unlikely to be of clinical significance
	• The majority of patients appear to be immunotherapy-responsive to first-line treatment, including one or more of the following: corticosteroids, intravenous immunoglobulin, and plasma exchange. Efficacy of second-line therapy remains to be systematically evaluated.
	• Delay in initiation of immunotherapy, delay in controlling faciobrachial dystonic seizures, and the presence of relapses are associated with poorer outcomes.

Historical note and terminology

Clinico-serological correlations. Autoimmune encephalitis is an increasingly recognized and understood clinical entity; many patients are found to have antibodies targeting domains of extracellular neuronal surface antigens, such as the N-methyl-D-aspartate (NMDA) receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, the gamma-aminobutyric acid (GABA) receptor, the glycine receptor, leucine-rich glioma inactivated 1 (LGI1) protein, and contactin-associated protein 2 (CASPR2), as well as numerous other less common targets (07; 56; 41). These antigens are thought to play a critical role in central nervous system synaptic transmission; hence, disruption of these targets is likely to result in cognitive and psychiatric manifestations as well as seizures. These neuronal surface antibody syndromes share some common paradigms: the target epitope is extracellular in location, and autoantibody binding is conformationally-sensitive. Hence, the native antigen is accessible to circulating autoantibodies. Also, the antibodies may alter the density and function of receptors; the clinical manifestations may be severe but are typically responsive to immunotherapy; and finally, the clinical phenotypes may be reminiscent of animal models of pharmacological or genetic dysfunction of the specific antigen in question.

Antibodies targeting the voltage-gated potassium channel, a transmembrane ion channel, were previously identified in 3 primary neurologic syndromes: limbic encephalitis, neuromyotonia, and Morvan syndrome (21). Limbic encephalitis is a CNS condition characterized by confusion and psychiatric changes, amnesia, seizures, and in several cases, hippocampal swelling on brain MRI. Neuromyotonia is a peripheral nervous system disorder characterized by peripheral nerve hyperexcitability that manifests as muscle cramps and stiffness. Morvan syndrome has features of both peripheral nervous system hyperexcitability and CNS disturbance with encephalopathy as well as autonomic dysfunction and insomnia (21). Neuromyotonia and Morvan syndrome have paraneoplastic associations, mostly with thymomas, particularly in Morvan syndrome (21). These 3 disorders share a commonality in that they are often subacute in onset, patients share overlapping features, and they often respond to immunotherapy (21; 33).

Revision of the underlying biochemistry. Antibody binding to the VGKC was previously detected using the pattern of immunostaining in rodent brain tissue and, most commonly, a radioimmunoprecipitation assay employing alpha-dendrotoxin-labelled VGKC channels from mammalian brain lysates (21; 30; 54). Alpha-dendrotoxin binds with high affinity to 3 specific VGKC subunits: Kv1.1, 1.2, and 1.6 (21), and these were initially thought to be the antigenic targets (29). However, cell-based assays, using direct transfection of a native full-length human antigen into a live human cell line revealed that the majority of patients in fact had antibodies that targeted 2 main proteins complexed with the VGKC; specifically, LGI1 and CASPR2 (21; 30). Hence, the term VGKC-complex antibodies was used to describe this collective group. Patients with LGI1 antibodies were more likely to have a limbic encephalitis presentation with prominent seizures, whereas those with CASPR2 antibodies more commonly showed neuromyotonia, dysautonomia, and neuropathic pain as well as typical limbic encephalitis. A direct comparison between LGI1- and CASPR2-antibody encephalitis is outlined in Table 1.

Table 1. Comparison of LGI1- and CASPR2-Antibody Autoimmune Encephalitis

	LGI1	CASPR2
Localization	64 kDa secreted protein expressed in hippocampus and neocortex	148 kDa cell adhesion molecule and a member of the neurexin intravenous superfamily, colocalizes with Kv1.1 and Kv1.2 at neural juxtaparanodes
Most commonly associated syndromes	CNS involvement: limbic encephalitis, faciobrachial dystonic seizures, other seizure types	CNS and PNS involvement: limbic encephalitis, Morvan syndrome, neuromyotonia
Demographics	Adults, median age of onset 60 to 70 years of age (range, 20s to 90s) 2:1 male: female ratio Extremely rare in children, with no support for testing in pediatric patients with encephalopathy and seizures	Adults, median age of onset 60 to 70 years of age (range 20s to 90s) 80% to 90% males Extremely rare in children
Antibody subtype	IgG4 greater than IgG1	IgG4 greater than IgG1
Clinical features	Seizures, amnesia, confusion, hyponatremia (in 60% to 75%) Cognitive impairment (in over 90%) (particularly verbal and visuospatial domains) Seizures in up to 90%; faciobrachial dystonic seizures 50%; focal seizures 65% (dyscognitive/autonomic); generalized tonic-clonic seizures 60% Sleep disturbance, insomnia in up to 50% Less commonly, pain (15%), cerebellar ataxia, chorea, parkinsonism, dystonia, severe bradycardia, and other arrhythmias	Seizures in over half the patients, amnesia, hyponatremia more rare Neuromyotonia, neuropathic pain (up to 40%), insomnia, dysautonomia, hyperhidrosis, and weight loss are more common More chronic cognitive impairment (sometimes resembling dementia phenotype) Sleep disturbance (agrypnia excitata most distinctively) Less commonly, hyponatremia, cerebellar ataxia, chorea, orthostatic myoclonus, arrhythmias CASPR2-antibody patients with thymomas often have AChR-antibody myasthenia gravis
Radiology	Acutely, medial temporal lobe (hippocampal changes) on MRI, may have contralateral basal ganglia involvement with faciobrachial dystonic seizures May be normal in around 50% Long-term, hippocampal atrophy and whole brain atrophy more common; mesial temporal sclerosis present; reduction in pallidal volume with faciobrachial dystonic seizures	Often T2 hippocampal hyperintensities Can be normal in around 70%
CSF	Often unremarkable in close to 75% Minority have CSF pleocytosis or elevated protein Rare to have intrathecal IgG synthesis	Normal in 60% to 70%
Paraneoplastic associations	Less common, 0% to 11%; thymoma, lung cancer, neuroendocrine pancreas tumor, abdominal mesothelioma	More common, 20% to 30%: mainly thymomas; also lung cancer, endometrial adenocarcinoma
Therapeutic response	Improvement with immunotherapy, particularly with regard to seizure cessation and control in response to corticosteroids	Improvement with immunotherapy in those without tumor associations, less of a response in those with tumor association Management of underlying neoplasia essential in those with tumor
Outcomes and prognosis	Memory impairment and cognitive impairment present as long-term sequelae, particularly in the absence of early and appropriate immunotherapy; mortality rate reported between 6% to 19%	Over 70% have a favorable outcome with immunotherapy 10% fatality rate
Relapse rate	0% to 35%	0% to 32%
(21; 26; 30; 34; 54; 55; 51; 05; 07; 49; 56; 41)

Although the pathogenic role of LGI1 or CASPR2 antibodies is increasingly clear, the role of VGKC-complex antibodies without antibodies to either LGI1 or CASPR2 is important to consider, not least because these may account for more than 60% of the VGKC antibody-positive results (53). These “double-negative” patients do not form a uniform subgroup; rather, they are clinically heterogenous with presentations including epilepsy, neuropathic pain, sleep disorders, or Creutzfeldt-Jacob disease, and there appear to be very limited correlations between VGKC-complex antibody levels and clinical severity (van Sonderen et al 2010a; 34; 09; 31). Indeed, up to 5% of community controls may be positive for VGKC-complex antibodies (57). Furthermore, it was additionally found that antibodies to CASPR2, and less commonly LGI1, were also detected in patients with absent VGKC-complex antibodies (26; 53). A study identified that double negative VGKC-complex antibodies very rarely bind the surface of live neurons in culture, and many are definitively proven to target cytosolic epitopes of Kv1 subunits or the non-mammalian alpha-dendrotoxin (31). Therefore, the presence of VGKC-complex antibodies in the absence of antibodies to LGI1 or CASPR2 is of doubtful clinical or biological relevance; evidence for pathogenic potential is lacking; and these antibodies do not seem to correlate with a distinct immunotherapy-responsive syndrome.

For these reasons, a firm move should be made toward testing specifically for LGI1 and CASPR2 antibodies in the appropriate clinical setting in order to enhance the sensitivity and specificity of diagnosis and optimize clinical translatability.

Clinical manifestations

Presentation and course

• Faciobrachial dystonic seizures can precede the onset of cognitive impairment.

The vast majority of patients with LGI1 antibodies have CNS involvement with limbic encephalitis symptoms (21; 30; 58; 04; 55). Cognitive impairment and seizures are among the most common presentations (53). Faciobrachial dystonic seizures are thought to be pathognomonic for LGI1 antibodies and are present in about 60% of patients with the antibodies (22; 24; 26; 53a; 55). Faciobrachial dystonic seizures are adult-onset, brief (usually 1 to 3 seconds) seizures involving posturing of the hemiface and ipsilateral arm, with a dystonic semiology (24; 26). Events are stereotyped and frequent (8 to 200 per day, median 50 per day) (26; 56). Faciobrachial dystonic seizures are often triggered by kinesigenic or emotive stimuli and can be preceded by a sensory aura, associated with ictal automatisms, and have postictal speech arrest, fear, or agitation following the motor event (26). Interestingly, auditory auras are not associated with faciobrachial dystonic seizures, although they are the prominent features of patients with mutations in LGI1 (39). Faciobrachial dystonic seizures can alternate sides in an individual patient. Associated falls or dropping items are common findings likely due to involvement of the leg and arm, respectively.

Importantly, faciobrachial dystonic seizures can precede the onset of cognitive impairment or, less commonly, can occur concurrently with the cognitive dysfunction (26; 55). The cognitive impairment is frequently florid but can be insidious in onset, which increases the risk of delayed recognition, underdiagnosis, or misdiagnosis (26).

Other seizure semiologies described in around 70% of LGI1 antibody-positive patients include dyscognitive or autonomic focal seizures and motor or gelastic seizures (55; 03). The autonomic involvement can lead to bradycardia and pacemaker-necessitating asystole (38). The most commonly reported sensory events were thermal sensations or body-shuddering, and motor events were most frequently identified as automatisms or vocalizations (03). Generalized tonic-clonic seizures can occur in up to 63% of patients (55; 03). Finally, in one report, paroxysmal dizzy spells also appeared to be characteristic of patients with LGI1 antibodies (17).

The clinical manifestations of LGI1- and CASPR2-antibody encephalitis share significant similarities, including clinical presentations with limbic encephalitis, seizures, sleep disturbances, and neuromyotonia, and investigation findings including serum hyponatremia and medial temporal changes on MRI (07). Therefore, these 2 antibody-mediated syndromes perhaps exist on a spectrum. Faciobrachial dystonic seizures, however, appear exclusive to patients with LGI1 antibodies. Of interest, close to 50 patients who have double-positive antibodies to both LGI1 and CASPR2 have been reported in the literature and lend further weight to the suggestion that these disorders may share an underlying pathogenesis (07). Over 40% of these double-positive patients are found to have a paraneoplastic association, with a third being thymomas (17). Rare phenotypes, including cerebellar ataxia, chorea, parkinsonism, and dystonia, have also been identified in some LGI1- and CASPR2-antibody patients (50; 47; 51).

Sleep disturbances have been identified in LGI1-antibody encephalitis with disruption of both REM and NREM sleep and hyperkinetic movements during the active phase of the disease, and evolution into REM sleep behavior disorder or periodic limb movement syndrome in some patients during the recovery phase (32).

Clinical vignette

A 92-year-old man presented with a 5-month history of right facial grimacing and simultaneous right-arm dystonic posturing lasting seconds. He was previously independent with activities of daily living and at the time of symptom onset had normal cognition. The episodes of right hemifacial and ipsilateral arm twitching could occur up to 8 times a day, and he had no recollection of these episodes.

Within a month following onset, he developed deficits in memory and was noted to be more withdrawn and confused but was still living independently. By 3 months post-onset, he was getting lost within his own home and having difficulty recognizing and naming objects. He had recurrent falls, some resulting in injuries such as wrist fractures. Seizures were suspected, and levetiracetam 250 mg twice daily was commenced without effect.

He was reviewed in a tertiary hospital clinic at 4 months post-onset. On examination, there were no localizing neurologic signs; however, cognitive examination revealed impaired orientation, attention, memory, and visuospatial deficits. The Addensbrooke Cognitive Examination Revised (ACER) score was 64/100. He had mild hyponatremia at 132 mmol/L. Prolonged EEG monitoring recorded stereotyped episodes with rhythmical theta activity in left temporal area, followed by focal sharp waves in the mid temporal area, consistent with left hemispheric focal seizure activity. Serum LGI1 antibodies were positive. MRI demonstrated chronic small vessel disease and normal imaging of the hippocampus. A 3-day course of 1 g intravenous methylprednisolone per day completely abolished seizures. The patient was subsequently commenced on 40 mg daily of prednisone, weaned over a 4-week period.

ACER ratings 1 week after steroids were commenced demonstrated a 10-point improvement to 74/100, and within 2 months after treatment commencement this further increased to 84/100. However, 5 months after steroid cessation (10 months after symptom onset), he presented with a recurrence of seizures that once again ceased rapidly on recommencement of 40 mg daily prednisone. This was weaned over a 7-month period, and the patient maintained remission even after cessation of steroids and discontinuation of levetiracetam. ACER 1 year after symptom onset was 93/100, and the patient had returned to his baseline function and cognition.

Biological basis

Etiology and pathogenesis

	• LGI1 and CASPR2 antibodies are primarily of the IgG4 subclass.
	• Mice infused with patient-derived LGI1 antibodies show severe memory deficits that improve after cessation of the infusion.

LGI1 is a secreted protein that is thought to play an important role in transmission between presynaptic and postsynaptic complexes (21; 30). LGI1 interacts with, and acts as a ligand for, 2 synaptic proteins of the disintegrin and metalloproteinase domain (ADAM) family, specifically ADAM22 postsynaptically and ADAM23 presynaptically (15).

LGI1 and CASPR2 antibodies are primarily of the IgG4 subclass. If they are bispecific and express 2 distinct antigen-binding sites, as has been reported for some IgG4 antibodies, they may be less efficient at crosslinking. Furthermore, IgG4 antibodies cannot activate complement (05; 51; 07). Instead, their mode of action is primarily thought to be through direct modulation or functional interference of protein-protein interactions or associated proteins.

In vitro and in vivo studies using patient derived monoclonals and unfractionated patient IgGs have shown that LGI1 antibodies from limbic encephalitis patients inhibit the interaction between LGI1 and ADAM22/23 and reversibly reduce synaptic AMPA receptor clusters in rat hippocampal neurons (39). In addition, both IgG4 and IgG1 LGI1 antibodies may cause internalization of the LGI1-ADAM22 complex (49; 43). Taken together, these findings suggest that LGI1-ADAM22 modulation may reduce and disrupt AMPA receptor function (39; 43), which, in turn, may result in increased excitability and CNS manifestations including seizures. Additionally, genetic LGI1 deficiency has been shown to result in down-regulation of Kv1.1 and Kv1.2 expression, which provides another epileptogenic mechanism (45). The LGI1-ADAM22 complex associates with postsynaptic density protein 95 family membrane-associated granulate kinases (MAGUKs) to organize transsynaptic protein networks such as NMDA and AMPA receptors and Kv1 channels. Mouse models with disruption of LGI1-ADAM22-MAGUK interactions exhibited lethal epilepsy (16).

Moreover, mice infused with patient-derived IgG showed severe memory deficits in novel object recognition, which improved after cessation of the infusion (40). In one study, LGI1 antibodies in sera and CSF were shown to bind to both domains of LGI1 (leucine-rich repeat or LRR; and epitempin repeat or EPTP) (43). However, patient-derived monoclonal antibodies demonstrated mutually exclusive binding to one of these 2 domains, with varied binding strengths and characteristics. LRR-binding monoclonal antibodies demonstrated binding to rodent brain sections, induced internalization of the LGI1-ADAM22/23 complex in HEK293T cells and live hippocampal neurons, and in an in vivo model; those LRR-binding monoclonal antibodies with higher binding strength resulted in memory impairment (43). Some of these effects were mimicked with EPTP binding monoclonals.

Only a few studies evaluate the histopathology of patients with LGI1-antibody encephalitis. One study describes CD45+ and CD8+ T cells in proximity to the hippocampus, with only mild neuronal loss, as well as in the meninges of the lateral temporal lobe and intraparenchymal vessels (44). Bien and colleagues describe immunohistopathological evidence of both immunoglobulin deposition and complement-mediated neuronal destruction in 4 patients with elevated VGKC-complex antibodies (with only 1 identified as having LGI1 antibodies) (06). This may be only part of the answer as it is now understood that most LGI1 antibodies are of the noncomplement-fixing IgG4 subtype. However, patients with faciobrachial dystonic seizures and cognitive impairment have been shown to have higher proportions of minority LGI1-IgG1 antibodies when compared to patients without cognitive impairment, suggesting complement activation may yet have a role in the irreversible cognitive sequelae of LGI antibodies (49).

Genetic data show that patients with LGI1 antibodies have human leukocyte antigen DRB1*07:01 through DQB1*02:02 haplotypes, present in 90% of LGI1-antibody limbic encephalitis patients from East Asian and Caucasian cohorts (28; 52; 07). The identification of human leucocyte antigen susceptibilities provides the impetus to study the relevance of T cell interactions in an autoantibody-driven disease process. It further raises the possibility of an underlying genetic predisposition activated by a second hit such as an infection, environmental trigger, or tumor to trigger the clinical manifestations of the condition (07).

Persistent cognitive impairment has been described in a few LGI1-antibody patients with hippocampal atrophy and elevated flortaucipir retention on PET scanning, suggesting tau neuropathology may associate with cognitive impairment in stable LGI1 patients (10). Hence, some neurodegeneration may coexist with an autoimmune pathology in some patients with permanent deficits following this autoimmune encephalitis.

Differential diagnosis

A diagnosis of possible autoimmune encephalitis applies to patients with a subacute onset of memory deficits, altered mental state, or psychiatric symptoms plus at least one of the following: new focal CNS findings; otherwise unexplained seizures; CSF pleocytosis; MRI features suggestive of encephalitis; and reasonable exclusion of alternative causes. These presentations should prompt appropriate testing for antibodies to neuronal surface antigens (19). Clinical features suggestive of specific autoimmune encephalitic syndromes, such as the stereotyped movement disorders in NMDAR-antibody encephalitis or the faciobrachial dystonic seizures associated with LGI1 antibodies, may help direct testing. In the absence of these clinical pointers, screening investigations for the range of available neuronal surface antibody syndromes may be reasonably performed.

Autoimmune encephalitis associated with antibodies targeting onconeural intracellular antigens, such as cytoplasmic or nuclear proteins (eg, Ma, Hu, and Ri), are often paraneoplastic with a progressive course, typically despite immunotherapies, and with a typically guarded prognosis (06; 42). Treatment should be primarily directed to the underlying neoplasia, and neuronal cell death is primarily attributed to T-cell-mediated neurotoxicity, suggesting that these antibodies are not primarily pathogenic but, rather, biomarkers of associated tumors (06). This antibody panel should be performed if there are concerns of a paraneoplastic neurologic presentation with rapidly progressive neurologic deficits, detected tumor, or lack of response to immunotherapy.

Other CNS inflammatory syndromes, including stiff person syndrome, progressive encephalomyelitis with rigidity and myoclonus, Bickerstaff encephalomyelitis, and Hashimoto encephalopathy, should also be considered in the presence of specific neurologic features associated with these syndromes, and testing for antibodies to glutamic acid decarboxylase, the glycine receptor, GQ1b, and thyroid antibodies can be pursued as deemed clinically relevant (19). Morvan syndrome and Rasmussen encephalitis generally have a more chronic course but may be considered in the differential diagnosis of atypical presentations of encephalopathy (19).

An important differential diagnosis for autoimmune encephalitis in a patient presenting with acute or subacute CNS involvement and cognitive impairment is Creutzfeldt-Jacob disease (18). The faciobrachial dystonic seizures associated with LGI1 antibodies may be misdiagnosed as myoclonus associated with Creutzfeldt-Jacob disease. Although the prevalence is low, evaluation for LGI1 antibodies and potentially other neuronal surface antibodies should be considered in patients with suspected Creutzfeldt-Jacob disease. A fascinating case report highlights a patient with faciobrachial dystonic seizures, limbic encephalitis, and LGI1 antibodies plus consistent radiology who demonstrated a complete response to immunotherapy and who subsequently experienced a rapidly progressive dementia with postmortem confirmation of Creutzfeldt-Jacob disease. This case draws attention to a rare example of these 2 conditions occurring in the same individual (27).

Diagnostic workup

	• Electroencephalography during faciobrachial dystonic seizures is often normal.
	• Brain MRI demonstrates increased T2 signal and swelling in the medial temporal lobe in 50% to 74% of patients.

Hyponatremia is identified in up to 60% of patients and provides a helpful paraclinical clue that is easily available in all clinical settings (30). It may be secondary to LGI1 antibodies binding the hypothalamic ADH-secreting neurons (25).

Electroencephalography during faciobrachial dystonic seizures is often normal, and ictal localization has been noncontributory in most patients. In a minority of faciobrachial dystonic seizures, there is evidence of preceding focal rhythmic delta wave activity and focal discharges or slowing immediately following the motor event (26; 03). EEG may additionally show multifocal interictal epileptiform discharges during other focal seizure types or focal slowing interictally; extending beyond the expected temporal localization to also encompass discharges arising from the frontal and parietal regions (55; 03). Multiple seizure semiologies, subclinical seizures, and interictal epileptiform discharges appear to be characteristic of LGI1-antibody encephalitis (03).

MRI may demonstrate changes including increased T2 signal and swelling in the medial temporal lobe in 50% to 74% of patients (21; 30; 54; 55). Signal changes in the basal ganglia are almost uniquely present in patients with faciobrachial dystonic seizures, typically contralateral to the side of limb and hemiface involvement (26; 14; 17).

CSF is normal in up to 75% of patients, and inflammatory changes, such as lymphocytic pleocytosis and elevated protein levels, are not present in the majority of patients (55). Only a minority have intrathecal oligoclonal bands. Serum testing for LGI1 antibodies additionally appears to be more sensitive and specific when compared with CSF (55; 51; 17). Indeed, patients with CSF negative for LGI1-antibodies were clinically indistinguishable from those with both serum and CSF LGI1-antibodies (37).

Management

	• Faciobrachial dystonic seizures are often refractory to multiple antiepileptic drugs.
	• Steroids are the main treatment. Although seizure response may be rapid within days to weeks, improvement in cognition is typically slower and may take months.

Overall, a third of patients with faciobrachial dystonic seizures experience these in isolation, often with normal sodium levels, CSF analysis, and MRI. Those who go on to develop limbic encephalitis with associated cognitive impairment may demonstrate other seizure semiologies, including more typical mesial temporal lobe seizures as well as hyponatremia and hippocampal T2 hyperintensity on imaging (24; 26; 49). Hence, again, clinical diagnosis is at the forefront of management.

Faciobrachial dystonic seizures are often refractory to multiple antiepileptic drugs, despite use of a median of 3 agents (range 1 to 10). Also, 29% to 50% of patients have serious cutaneous drug reactions to antiepileptic drugs (24; 26; 49). Only 10% of patients with faciobrachial dystonic seizures responded to antiepileptic drugs alone, and these patients tended to have a milder phenotype (49).

In contrast, the majority of patients with faciobrachial dystonic seizures respond well, often within weeks, to the initiation of immunotherapy. Many cases responded even within 2 weeks. This immunotherapy is used in addition to antiepileptic drugs or in isolation (24; 26). A study evaluating 103 patients with faciobrachial dystonic seizures identified that 51% of patients responded with cessation of faciobrachial dystonic seizures to immunotherapy within 1 month of initiation (26; 49). This rapid response suggests that steroids may have antibody-independent effects on seizure control (26). The benefit of immunotherapy over anticonvulsant therapy in seizure cessation has been reproduced in other cohorts (11). In the first randomized controlled trial within the field, intravenous immunoglobulin was superior to placebo in reducing seizure frequency by 50% in patients with LGI1-antibody encephalitis (12). However, this study was limited by a relatively small number of patients.

Although seizure response may be rapid within days to weeks, improvement in cognition is typically slower and may take months to years (51). The need for ongoing immunotherapy may be met with oral corticosteroids, alone or in combination with steroid-sparing agents such as azathioprine or mycophenolate (51). However, the value of such slow-acting agents is unclear. Response to second-line therapies, including cyclophosphamide or rituximab, has only been evaluated in small numbers of patients; although effective in a few patients, the impact on others has been, perhaps surprisingly, limited (23; 54; 05). This likely reflects the fact that outcome measures in these patients are confounded by delay in initiation of second-line immunotherapy and that selection bias dictates that more severely affected patients receive second-line therapy. Further prospective studies with larger numbers of patients on these agents are required to provide empirical evidence for their utility and efficacy. Although seizures are common in the early stage of LGI1-antbody encephalitis, once the disease course is stabilized with immunotherapy, patients appear to be unlikely to go onto develop epilepsy. In seizure free patients, withdrawal of anticonvulsants in the medium to long-term does not appear to result in ongoing seizures (11; 20).

Immunotherapy in the context of antibody seropositivity in unselected patients with new-onset seizures was shown to benefit patients with some subtle features of encephalitis, such as attentional deficits and affective disturbances, providing a method to select patients presenting to first-seizure clinics who will benefit from immunotherapy (35).

Although in some patients, clinical course appears to be broadly reflected in antibody levels, this correlation is imperfect and should not be used to guide therapy (19). Indeed, serum LGI1 antibodies may remain positive for prolonged durations despite clinical remission and recovery (02). Taken together, this suggests that management should focus on the clinical status of the patient, hence, the value in better understanding clinical trajectories and outcomes.

Outcomes

There are infrequent reports of patients with LGI1-antibody limbic encephalitis where the diagnosis was made retrospectively, 36 and 53 months after symptom onset, and patients did not receive immunotherapy (48). Both patients in this well-described report achieved seizure freedom and a monophasic natural history with recovery without relapses. However, in other cases, multiple relapses were noted over the course of a decade (01). Although the possibility of spontaneous resolution of seizures suggests a more benign course, it is of note that follow-up imaging revealed global brain atrophy and hippocampal sclerosis in one patient and either mild or moderate cognitive impairment, particularly in domains of memory and verbal fluency, in both patients (48).

If faciobrachial dystonic seizures are treated adequately and proactively with immunotherapy, there is a significant reduction in the development of cognitive impairment (26; 49), whereas, patients with ongoing seizures show a poorer cognitive outcome. In a cohort of 103 patients with faciobrachial dystonic seizures, 56% of patients who had faciobrachial dystonic seizures as their first presentation developed cognitive impairment after 90 days of active seizures; compare this to only one patient who developed cognitive impairment after cessation of faciobrachial dystonic seizures (49). This suggests that the effective termination of faciobrachial dystonic seizures may prevent the onset of cognitive impairment, which typically defines the encephalitis.

Relapses of seizures and cognitive impairment have been documented in patients with LGI1 antibodies, particularly in the context of steroid tapering and withdrawal, with amelioration of symptoms with reinstitution of steroids (26). Patients with faciobrachial dystonic seizures, irrespective of the presence of hippocampal changes in the acute phase, may go on to have smaller whole-brain volumes compared to controls (26). Longer duration of faciobrachial dystonic seizures has been additionally shown to be associated with a reduction in pallidal volume (13). Even in patients who have received immunotherapy, cohort studies have identified mesial temporal sclerosis in up to 44% (55).

Although up to 80% of patients who receive immunotherapy have a favorable response with a rapid benefit in terms of seizure control, improvement in cognition may be slower and incomplete, with many patients reporting lasting cognitive deficits (55; 17). Retrograde amnesia for the period of the acute illness is a common sequela (55). Verbal and visuospatial memory deficits, with associated hippocampal atrophy and interruption of hippocampal microstructural integrity, is common (13). In addition, apathy is noted in many patients (55; 13). Delayed initiation of immunotherapy was associated with worse verbal and visuospatial episodic memory performance (13). Patients with increased clinical severity, often reflected in failure to respond to second line therapy, had more severe hippocampal structural damage, which in turn was associated with worse memory performance (13).

Overall, expedited immunotherapy and normal cognition at baseline are the best predictors of reduced disability at 24 months (49). Those without an initial response to immunotherapy and those who experienced relapses had a worse prognosis (02). Telehealth follow up in 37 patients identified that premorbid cognitive reserve and MRI with bilateral hippocampal hyperintensity were predictors for long-term cognitive impairment (46). Furthermore, high seizure frequency may be associated with more limited recovery rates (03). In one study, relapses have been reported in up to 35% of patients and may implicate utility of chronic immunotherapy in a subgroup of patients. The impact of impaired cognition, but more so fatigue and mood disorders, may result in insidious long-term residual deficits in patients, impairing the employment status and quality of life of patients with LGI1-antibody encephalitis (08).

Taken together, these findings provide a compelling argument that early diagnosis and the rapid institution of appropriate immunotherapy in LGI1-antibody encephalitis is essential to prevent irreversible long-term sequelae. Refinement of outcome measures is critical as functional scales such as the mRS may underestimate the impact of factors such as cognitive impairment and fatigue on quality of life (46; 08).

References

01: Agazzi P, Bien CG, Staedler C, Biglio V, Gobbi C. Over 10-year follow-up of limbic encephalitis associated with anti-LGI1 antibodies. J Neurol 2015;262(2):469-70. PMID 25504306
02: Arino H, Armangue T, Petit-Pedrol M, et al. Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 2016;87(8):759-65. PMID 27466467
03: Aurangzeb S, Symmonds M, Knight RK, Kennett R, Wehner T, Irani SR. LGI1-antibody encephalitis is characterized by frequent, multifocal clinical and subclinical seizures. Seizure 2017;50:14-7. PMID 28586706
04: Bakpa OD, Reuber M, Irani SR. Antibody-associated epilepsies: clinical features, evidence for immunotherapies and future research questions. Seizure 2016;41:26-41. PMID 27450643
05: Bastiaansen AEM, van Sonderen A, Titulaer MJ. Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies). Curr Opin Neurol 2017;30(3):302-09. PMID 28248701
06: Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012;135(Pt 5):1622-38. PMID 22539258
07: Binks SN, Klein CJ, Waters P, Pittock SJ, Irani SR. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry 2018;89(5):526-34** PMID 29055902
08: Binks SNM, Veldsman M, Easton A et al. Residual fatigue and cognitive deficits in patients after leucine-rich glioma-inactivated 1 antibody encephalitis. JAMA Neurol 2021;78(5):617-9. PMID 33779685
09: Celicanin M, Blaabjerg M, Maersk-Moller C, et al. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study. Eur J Neurol 2017;24(8):999-1005. PMID 28544133
10: Day GS, Gordon BA, McCullough A, et al. Flortaucipir (tau) PET in LGI1 antibody encephalitis. Ann Clin Transl Neurol 2021;8(2):491-7. PMID 33410601
11: de Bruijn MAAM, van Sonderen A, van Coervorden-Hameete, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology 2019;92(19):e2185-96. PMID 30979857
12: Dubey D, Britton J, McKeon A, et al. Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 encephalitis. Ann Neurol 2020;87(2):313-23. PMID 31782181
13: Finke C, Pruss H, Heine J, et al. Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol 2017;74(1):50-9. PMID 27893017
14: Flanagan EP, Kotsenas AL, Britton JW, et al. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm 2015;2(6):e161. PMID 26468474
15: Fukata Y, Adesnik H, Iwanaga T, Bredt DS, Nicoll RA, Fukata M. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science 2006;313(5794):1792-5. PMID 16990550
16: Fukata Y, Chen X, Chiken S, et al. LGI1-ADAM22-MAGUK configures transsynaptic nonalignment for synaptic transmission and epilepsy prevention. Proc Natl Acad Sci USA 2021;118(3):e2022580118. PMID 33397806
17: Gadoth A, Pittock SJ, Dubey D, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol 2017;82(1):79-92. PMID 28628235
18: Grau-Rivera O, Sanchez-Valle R, Saiz A, et al. Determination of neuronal antibodies in suspected and definite Creutzfeldt-Jakob disease. JAMA Neurol 2014;71(1):74-8. PMID 24248099
19: Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15(4):391-404. PMID 26906964
20: Ilyas-Feldmann M, Press H, Holtkamp M. Long-term seizure outcome and antiseizure medication use in autoimmune encephalitis. Seizure 2021;86:138-43. PMID 33618141
21: Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133(9):2734-48.** PMID 20663977
22: Irani SR, Buckley C, Vincent A, et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 2008;71(20):1647-8. PMID 18815385
23: Irani SR, Gelfand JM, Bettcher BM, Singhal NS, Geschwind MD. Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy. JAMA Neurol 2014;71(7):896-900. PMID 24842754
24: Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69(5):892-900. PMID 21416487
25: Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012;72(2):241-55. PMID 22473710
26: Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013;136(Pt 10):3151-62. PMID 24014519
27: Kim B, Yoo P, Sutherland T, et al. LGI1 antibody encephalopathy overlapping with sporadic Creutzfeldt-Jakob disease. Neurol Neuroimmunol Neuroinflamm 2016;3(4):e248. PMID 27354985
28: Kim TJ, Lee ST, Moon J, et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes. Ann Neurol 2017;81(2):183-92.** PMID 28026029
29: Kleopa KA, Elman LB, Lang B, Vincent A, Scherer SS. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain 2006;129(Pt 6):1570-84. PMID 16613892
30: Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9(8):776-85. PMID 20580615
31: Lang B, Makuch M, Moloney T, et al. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. J Neurol Neurosurg Psychiatry 2017;88(4):353-61. PMID 28115470
32: Liu X, Yang L, Han Y, et al. Electrophysiological evaluation in identifying unique sleep features among anti-LGI1 encephalitis patients during active and recovery phase. Nat Sci Sleep 2021;13:527-36. PMID 33976578
33: Machado S, Pinto AN, Irani SR. What should you know about limbic encephalitis? Arq Neuropsiquiatr 2012;70(10):817-22. PMID 23060110
34: Malter MP, Frisch C, Schoene-Bake JC, et al. Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. J Neurol 2014;261(9):1695-705. PMID 24935858
35: McGinty RN, Handel A, Moloney T, et al. Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapies. J Neurol Neurosurg Psych 2021;92(3):291-4. PMID 33219046
36: Michael S, Waters P, Irani S. Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2. Practical Neurology 2020;20(5):377-84. PMID 32595134
37: Muniz-Castrillo S, Haesebaert J, Thomas L, et al. Clinical and prognostic value of immunogenetics characteristics in anti-LGI1 encephalitis. Neurol Neuroimmunol Neuroinflamm 2021;8(3):e974. PMID 33848259
38: Naasan G, Irani SR, Bettcher BM, Geschwind MD, Gelfand JM. Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis. JAMA Neurol 2014;71(10):1300-04. PMID 25133690
39: Ohkawa T, Fukata Y, Yamasaki M, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013;33(46):18161-74. PMID 24227725
40: Petit-Pedrol M, Sell J, Planaguma J, et al. LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain 2018;141(11):3144-59. PMID 30346486
41: Ramanathan S, Al-Diwani A, Waters P et al. The autoantibody mediated encephalitis: from clinical observations to molecular pathogenesis. J Neurol 2021;268(5):1689-707. PMID 31655889
42: Ramanathan S, Mohammad SS, Brilot F, Dale RC. Autoimmune encephalitis: recent updates and emerging challenges. J Clin Neurosci 2014;21(5):722-30. PMID 24246947
43: Ramberger M, Berretta A, Tan JTT, et al. Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms. Brain 2020;143(6):1731-45. PMID 32437528
44: Schultze-Amberger J, Pehl D, Stenzel W. LGI-1-positive limbic encephalitis: a clinicopathological study. J Neurol 2012;259(11):2478-80. PMID 22648478
45: Seagar M, Russier M, Caillard O, et al. LGI1 tunes intrinsic excitability by regulating the density of axonal Kv1 channels." Proc Natl Acad Sci U S A 2017;114(29):7719-24. PMID 28673977
46: Sola-Valls N, Arino H, Escudero D, et al. Telemedicine assessment of long-term cognitive and functional status in anti-leucine rich, glioma inactivated 1 encephalitis. Neurol Neuroimmunol Neuroinflamm 2019;7(2):e652. PMID 31848230
47: Steriade C, Day GS, Lee L, Murray BJ, Fritzler MJ, Keith J. LGI1 autoantibodies associated with cerebellar degeneration. Neuropathol Appl Neurobiol 2014;40(5):645-49. PMID 24606111
48: Szots M, Marton A, Kover F, et al. Natural course of LGI1 encephalitis: 3-5 years of follow-up without immunotherapy. J Neurol Sci 2014;343(1-2):198-202. PMID 24928080
49: Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 2018;141(2):348-56.** PMID 29272336
50: Tofaris GK, Irani SR, Cheeran BJ, Baker IW, Cader ZM, Vincent A. Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis. Neurology 2012;79(2):195-6. PMID 22744657
51: van Sonderen A, Petit-Pedrol M, Dalmau J, Titulaer MJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol 2017a;13(5):290-301. PMID 28418022
52: van Sonderen A, Roelen DL, Stoop JA, et al. Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4. Ann Neurol 2017b;81(2):193-8. PMID 28026046
53: van Sonderen A, Schreurs MW, de Bruijn MA, et al. The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies. Neurology 2016a;86(18):1692-9. PMID 27037230
54: van Sonderen A, Schreurs MW, Wirtz PW, et al. From VGKC to LGI1 and Caspr2 encephalitis: the evolution of a disease entity over time. Autoimmun Rev 2016b;15(10):970-4. PMID 27485013
55: van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology 2016c;87(14):1449-56.** PMID 27590293
56: Varley J, Taylor J, Irani SR. Autoantibody-mediated diseases of the CNS: Structure, dysfunction and therapy. Neuropharmacology 2018;132:71-82. PMID 28476644
57: Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127(Pt 3):701-12. PMID 14960497
58: Vincent A, Irani SR, Lang B. Potentially pathogenic autoantibodies associated with epilepsy and encephalitis in children and adults. Epilepsia 2011;52 Suppl 8:8-11. PMID 21967350

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Sarosh R Irani MD

Dr. Irani of the University of Oxford received royalties from Nil as a patent joint applicant.
See Profile
Sudarshini Ramanathan MD

Dr. Ramanathan of the University of Oxford and University of Sydney has no relevant financial relationships to disclose.
See Profile

Editor

Francesc Graus MD PhD

Dr. Graus, Emeritus Professor, Laboratory Clinical and Experimental Neuroimmunology, Institut D’Investigacions Biomédiques August Pi I Sunyer, Hospital Clinic, Spain, has no relevant financial relationships to disclose.
See Profile

Patient Profile

Age range of presentation: 19 to 65+ years
Sex preponderance: Male > female
Heredity: None
Population groups selectively affected: None
Occupation groups selectively affected: None

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Anti-LGI1 encephalitis

Associated Disorders

limbic encephalitis
faciobrachial dystonic seizures
other seizure types

Differential Diagnosis

stiff person syndrome
progressive encephalomyelitis with rigidity and myoclonus
Bickerstaff encephalomyelitis
Hashimoto encephalopathy
Morvan syndrome
- Rasmussen encephalitis
- Creutzfeldt-Jacob disease

Also Relevant

Antibody-mediated epilepsies
Autoantibodies: disease markers
Hashimoto encephalopathy
Movement disorders associated with autoimmune encephalitis
Neuromyotonia and myokymia
- Paraneoplastic limbic encephalitis
- Paraneoplastic syndromes
- Rasmussen syndrome

Clinical Categories

Patient Handouts

Encephalitis

Anti-LGI1 encephalitis …

Anti-LGI1 encephalitis

Introduction

Overview

Key points

Historical note and terminology

Table 1. Comparison of LGI1- and CASPR2-Antibody Autoimmune Encephalitis

Clinical manifestations

Presentation and course

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Diagnostic workup

Management

Outcomes

References

Contributors

Authors

Editor

Patient Profile

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Autoantibodies: mechanism and testing

NF2-related schwannomatosis

Tumors of the skull base

Photosensitive occipital lobe epilepsy

Intermittent explosive disorder

Metal neurotoxicity

Multiple sclerosis: treatment of its symptoms

Vascular cognitive impairment

Anti-LGI1 encephalitis

Introduction

Overview

Key points

Historical note and terminology

Table 1. Comparison of LGI1- and CASPR2-Antibody Autoimmune Encephalitis

Clinical manifestations

Presentation and course

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Diagnostic workup

Management

Outcomes

References

Contributors

Authors

Editor

Patient Profile

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Autoantibodies: mechanism and testing

NF2-related schwannomatosis

Tumors of the skull base

Photosensitive occipital lobe epilepsy

Intermittent explosive disorder

Metal neurotoxicity

Multiple sclerosis: treatment of its symptoms

Vascular cognitive impairment

This is an article preview.
Start a Free Account
to access the full version.